The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of…
The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who…
An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new…
Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple…
The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating…
Positive data for the Phase 1 trial of PharmaMar’s plitidepsin combined with bortezomib and dexamethasone for the treatment of relapsed and/or refractory multiple…
Spain-based PharmaMar announced the company will present data from several clinical studies of three of its anti-tumoral compounds of marine origin — plitidepsin, Yondelis (trabectedin),…
Newton, Massachusetts-based Karyopharm Therapeutics has published the results from its Phase 1 trial of selinexor (KPT-330) in patients with advanced solid tumors in the…
Three organizations — CURE Media Group, Multiple Myeloma Research Foundation (MMRF) and Takeda Oncology — joined together in the Moving Mountains for Multiple…
Bristol-Myers Squibb (BMS) Company and AbbVie have announced that the European Commission (EC) has approved Empliciti™ (elotuzumab) for the treatment of multiple…